Zhitong Financial App News, Huiyu Pharmaceuticals (688553.SH) announced that Seacross Pharmaceuticals Ltd., a wholly-owned subsidiary of the company, recently received the approval and issuance of a marketing license from the UK Medicines and Health Products Administration (hereinafter referred to as the “UK Drug Administration”) for the company's product benzenesulfonate atracurium injection.
According to reports, benzenesulfonium atracurium injection is suitable for surgical and other surgical treatment for adults and children 1 month and older, and can also be used for intensive care treatment in adults. This product can be used as an aid to general anesthesia or as a sedative in ICU to relax skeletal muscles, which is beneficial for endotracheal intubation and mechanical ventilation.